Pharmacy & Therapeutics- July 2008 - (Page 383) Stable dosing PRECiSE Maintenance Therapy 2,4 n=141 30 25 20 15 10 0 Plasma concentration (µg/mL) 024 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 Weeks Chart represents patients in PRECiSE 2 who continued on CIMZIA therapy in PRECiSE 3 (n=141). Stable serum levels were achieved with no dose escalation in clinical trials8 PEGylation—enables Q4-week dosing8|| || Initial dose at weeks 0, 2, and 4 and then every 4 weeks as maintenance therapy. Predictable costs Stable dose, stable cost No dose escalation in clinical trials No weight-based dose adjustment necessary 2 200-mg subcutaneous injections—400-mg dose 2 Q4-week dosing recommended after an initial dose at weeks 0, 2, and 42 CIMZIA is indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis and other serious infections. Please see Important Safety Information and Brief Summary of full Prescribing Information on adjacent pages.
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.